Proximity to Discovery - University of Oxford
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Oxford (Lead Research Organisation)
- UNIVERSITY OF OXFORD (Collaboration)
- AstraZeneca (Collaboration)
- Ventana Systems Inc (Collaboration)
- KWI Group (Collaboration)
- CN Bio Innovations Ltd (Collaboration)
- P1vital Consortium (Collaboration)
- Abide Therapeutics (Collaboration)
- E G Technology (Collaboration)
- UCB Pharma (Collaboration)
- Carrick Therapeutics (Collaboration)
- Sygnature Discovery Ltd (Collaboration)
People |
ORCID iD |
Matthew Wood (Principal Investigator) |
Publications
Ansari MA
(2019)
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.
in eLife
Belessiotis-Richards A
(2020)
Coarse-Grained Simulations Suggest the Epsin N-Terminal Homology Domain Can Sense Membrane Curvature without Its Terminal Amphipathic Helix.
in ACS nano
Blobel GA
(2021)
Testing the super-enhancer concept.
in Nature reviews. Genetics
Campbell KR
(2016)
Order Under Uncertainty: Robust Differential Expression Analysis Using Probabilistic Models for Pseudotime Inference.
in PLoS computational biology
Chen YL
(2020)
Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation.
in The Journal of experimental medicine
Chen YL
(2019)
Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis.
in Science translational medicine
Cork MJ
(2020)
Atopic dermatitis epidemiology and unmet need in the United Kingdom.
in The Journal of dermatological treatment
Cox L
(2019)
Ageing here and now: current research and transformative therapies.
in Biogerontology
Cox L
(2022)
Therapeutic approaches to treat and prevent age-related diseases through understanding the underlying biological drivers of ageing
in The Journal of the Economics of Ageing
Cox LS
(2020)
Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults.
in The lancet. Healthy longevity
Cox LS
(2022)
Linking interdisciplinary and multiscale approaches to improve healthspan-a new UK model for collaborative research networks in ageing biology and clinical translation.
in The lancet. Healthy longevity
Cox LS
(2021)
Targeting aging cells improves survival.
in Science (New York, N.Y.)
Francis H
(2020)
Scalable In Vitro Production of Defined Mouse Erythroblasts
Fritzsche M
(2015)
CalQuo: automated, simultaneous single-cell and population-level quantification of global intracellular Ca2+ responses.
in Scientific reports
Handel AE
(2016)
Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics.
in Human molecular genetics
Hardman C
(2019)
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.
in The Journal of allergy and clinical immunology
Hentges LD
(2022)
LanceOtron: a deep learning peak caller for genome sequencing experiments.
in Bioinformatics (Oxford, England)
Higgs DR
(2021)
Author Correction: Enhancer-promoter interactions and transcription.
in Nature genetics
Higgs DR
(2020)
Enhancer-promoter interactions and transcription.
in Nature genetics
Jeziorska DM
(2022)
On-microscope staging of live cells reveals changes in the dynamics of transcriptional bursting during differentiation.
in Nature communications
Kamaladasa A
(2019)
Altered monocyte response to the dengue virus in those with varying severity of past dengue infection.
in Antiviral research
Description | All Party Parliamentary Group for Longevity - strategic advisory board member, also science, genomic and technology board member |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://appg-longevity.org/advisory-board |
Description | Authored key paper in All Party Parliamentary Group report: The Health of the Nation: a strategy for longer healthier lives |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
URL | https://appg-longevity.org/events-publications |
Description | House of Lords science and technology select committee: oral evidence |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
URL | https://parliamentlive.tv/Event/Index/1c0e8f76-2e8a-4e27-a297-4b4f2e9cb5f3 |
Description | House of Lords select committee science and technology - ageing, science and healthy living: written evidence |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
URL | http://data.parliament.uk/writtenevidence/committeeevidence.svc/evidencedocument/science-and-technol... |
Description | Longevity Forum |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
URL | https://www.thelongevityforum.com |
Description | Longevity Leaders: advising/influencing investment by large companies including pension funds in ageing research - round table discussant |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
URL | https://www.lsxleaders.com/longevity-leaders-congress |
Description | Master Investor: Investing in the age of longevity. Gave speech to financial leaders on emerging opportunities in ageing research |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Academic collaboration with commercial company |
Amount | $400,000 (USD) |
Organisation | Amway |
Sector | Private |
Country | United States |
Start | 04/2017 |
End | 04/2018 |
Description | Age-related bone fragility in type 1 diabetes - the role of bone cell senescence |
Amount | £398,000 (GBP) |
Funding ID | 19BX18LCRD |
Organisation | British Council |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2020 |
End | 01/2023 |
Description | Anaptysbio Research Grant |
Amount | £700,000 (GBP) |
Organisation | AnaptysBio |
Sector | Private |
Country | United States |
Start | 02/2017 |
End | 01/2019 |
Description | BBSRC case award with GSK |
Amount | £140,000 (GBP) |
Funding ID | BB/P504373/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2020 |
Description | British Medical Association |
Amount | £35,000 (GBP) |
Organisation | British Medical Association (BMA) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2012 |
End | 09/2014 |
Description | British Skin Foundation Grant |
Amount | £62,000 (GBP) |
Organisation | British Skin Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2014 |
End | 12/2015 |
Description | British Skin Foundation Large Research Awards |
Amount | £70,000 (GBP) |
Organisation | British Skin Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2008 |
End | 09/2011 |
Description | Celgene Fellowship |
Amount | £500,000 (GBP) |
Organisation | Bristol-Myers Squibb |
Department | Celgene |
Sector | Private |
Country | United States |
Start | 01/2016 |
End | 01/2020 |
Description | Comprehensive Research Network |
Amount | £1,700,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Clinical Research Network (CRN) |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2007 |
End | 03/2017 |
Description | EXPLORATORY/DEVELOPMENT GRANT |
Amount | $137,000 (USD) |
Funding ID | 1R21AI125886-01 |
Organisation | National Institutes of Health (NIH) |
Sector | Public |
Country | United States |
Start | 08/2016 |
End | 08/2018 |
Description | Emerson award |
Amount | £150,000 (GBP) |
Organisation | Emerson Collective |
Sector | Private |
Country | United States |
Start | 12/2019 |
End | 12/2021 |
Description | Identifying factors that restore DNA repair in ageing cells through WRN reactivation |
Amount | £74,140 (GBP) |
Organisation | United Kingdom Research and Innovation |
Department | UK SPINE Knowledge Exchange |
Sector | Public |
Country | United Kingdom |
Start | 03/2020 |
End | 02/2021 |
Description | Investigator Award |
Amount | £1,600,000 (GBP) |
Organisation | Wellcome Trust |
Department | Wellcome Trust Senior Investigator Award |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2016 |
End | 04/2021 |
Description | Investigator award: Innate-like T cells and integration of host defence |
Amount | £2,035,864 (GBP) |
Funding ID | 222426/Z/21/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2022 |
End | 01/2027 |
Description | Janssen collaborative research grant |
Amount | $1,600,000 (USD) |
Organisation | Johnson & Johnson |
Department | Janssen Pharmaceuticals |
Sector | Private |
Country | United States |
Start | 09/2013 |
End | 09/2015 |
Description | Johnson and Johnson collaborative research |
Amount | £100,000 (GBP) |
Organisation | Johnson & Johnson |
Sector | Private |
Country | United States |
Start | 01/2015 |
End | 12/2015 |
Description | MRC Experimental Medicine 2 |
Amount | £380,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2009 |
End | 09/2012 |
Description | MRC Proximity to Discovery Award |
Amount | £6,900 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2015 |
End | 11/2016 |
Description | MRC/UCB Antibody Discovery Initiative |
Amount | £250,000 (GBP) |
Funding ID | MC_EX_MR/R022550/1 |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2019 |
End | 12/2019 |
Description | NIHR Senioe Investigator |
Amount | £60,000 (GBP) |
Organisation | University of Leicester |
Department | NIHR Biomedical Research Centre |
Sector | Hospitals |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2022 |
Description | Oxford Biomedical Research Centre |
Amount | £1,000,000 (GBP) |
Organisation | Oxford University Hospitals NHS Foundation Trust |
Department | NIHR Oxford Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2007 |
End | 03/2017 |
Description | UCB Research grant |
Amount | £354,000 (GBP) |
Organisation | UCB Pharma |
Sector | Private |
Country | United Kingdom |
Start | 08/2016 |
End | 08/2018 |
Description | Wellcome Trust Collaboratiev Award |
Amount | £3,000,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2018 |
End | 04/2023 |
Description | Abide Therapeutics - Oxford Collaboration |
Organisation | Abide Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | Expertise in innate immunology in relation to the gut and inflammatory bowel disease. Preclinical work with human primary dendritic cells and colon tissue examining roles for the endocannabinoid system. |
Collaborator Contribution | Processing of samples using activity-based protein profiling and lipidomics. Expertise in the pharmacology of the endocannabinoid system. |
Impact | No publications yet. No patents arising. There are other Abide - Oxford collaborations but these are separate to our own collaboration. |
Start Year | 2014 |
Description | CN-Bio collaboration |
Organisation | CN Bio Innovations Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Analysis of innate responses in an in vitro hepatocyte model |
Collaborator Contribution | Expertise and experiments in in vitro model |
Impact | Developing tools to study innate responses in the liver |
Start Year | 2016 |
Description | Enhancing tumour specific immune responses for the treatment of ovarian cancer |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Access to ovarian cancer biology and computational work |
Collaborator Contribution | Immunology expertise and cancer antigene prediction. |
Impact | The Ovarian Cancer Action (OCA) international grand challenge award Publication by Cancer Cell in Feb 2020: " The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells" |
Start Year | 2016 |
Description | Expert in Residence at Oxford - Antony Brown |
Organisation | Carrick Therapeutics |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy for Oxford translational research community. |
Collaborator Contribution | Consultancy for Oxford translational researchers. |
Impact | N/A |
Start Year | 2021 |
Description | Expert in Residence at Oxford - Colin Dourish |
Organisation | P1vital Consortium |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy for Oxford translational researchers. |
Collaborator Contribution | Consultancy for Oxford translational researchers. |
Impact | Consultancy for Oxford translational researchers. |
Start Year | 2020 |
Description | Expert in Residence at Oxford - Karen Wei |
Organisation | KWI Group |
Country | United States |
Sector | Private |
PI Contribution | Consultancy for Oxford Researchers. |
Collaborator Contribution | Consultancy for Oxford translational researchers |
Impact | N/A |
Start Year | 2021 |
Description | Expert in Residence at Oxford - Laura Ferguson |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy for translational researchers. |
Collaborator Contribution | Consultancy for translational researchers. |
Impact | N/A |
Start Year | 2021 |
Description | Expert in Residence at Oxford - ROUZET AGAIBY |
Organisation | E G Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy for Oxford translational researchers. |
Collaborator Contribution | Consultancy support for translational research projects at Oxford. |
Impact | N/A |
Start Year | 2021 |
Description | Expert in Residence at Oxford - Rachel Helmsley |
Organisation | Sygnature Discovery Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy for Oxford Researchers. |
Collaborator Contribution | Consultancy for Oxford Researchers. |
Impact | Consultancy for Oxford translational researchers. |
Start Year | 2021 |
Description | Expert in Residence at Oxford - Simon Hollingsworth |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Consultancy Support for Oxford Researchers. |
Collaborator Contribution | Consultancy Support for Oxford Researchers. |
Impact | N/A |
Start Year | 2020 |
Description | License option taken by Roche ventana |
Organisation | Ventana Systems Inc |
Country | United States |
Sector | Private |
PI Contribution | License option taken by Roche ventana to develop our technology to a diagnostic test. |
Collaborator Contribution | Roche Ventana will validate and obtain the necessary approvals to proceed towards a diagnostic test |
Impact | License option |
Start Year | 2017 |
Description | MedImmune Collaboration |
Organisation | AstraZeneca |
Department | MedImmune |
Country | United Kingdom |
Sector | Private |
PI Contribution | Scientific collaboration with MedImmune |
Collaborator Contribution | Analysis of samples, data to be analysed and reported in publication |
Impact | Data generation |
Start Year | 2016 |
Description | UCB collaboration with Sansom & Stansfeld |
Organisation | UCB Pharma |
Country | United Kingdom |
Sector | Private |
PI Contribution | Dr Zara Sands (UCB) spent time in my lab and worked alongside students & postdocs to familiarize herself with our methods for simulation of complex cell membranes. Dr. Sands has now moved to another company, but we continue an active collaboration with Dr. Richard Taylor and Dr. Jiye Shih at UCB (UK). Dr. Shih has now also left UCB which has weakend the collaboration. |
Collaborator Contribution | Dr Zara Sands (UCB) spent time in my lab and worked alongside students & postdocs to familiarize herself with our methods for simulation of complex cell membranes. The collaboration continues (see above), focussing on membrane protein/lipid interactions. |
Impact | This has resulted in UCB supporting additional iCASE studentships in my group. A joint paper with UCB on a-synuclein has been published and 2 further collaborative papers with UCB are in the pipeline. |
Start Year | 2016 |
Description | UCB collaboration with Sansom & Stansfeld |
Organisation | UCB Pharma |
Country | United Kingdom |
Sector | Private |
PI Contribution | Dr Zara Sands (UCB) spent time in my lab and worked alongside students & postdocs to familiarize herself with our methods for simulation of complex cell membranes. Dr. Sands has now moved to another company, but we continue an active collaboration with Dr. Richard Taylor and Dr. Jiye Shih at UCB (UK). Dr. Shih has now also left UCB which has weakend the collaboration. |
Collaborator Contribution | Dr Zara Sands (UCB) spent time in my lab and worked alongside students & postdocs to familiarize herself with our methods for simulation of complex cell membranes. The collaboration continues (see above), focussing on membrane protein/lipid interactions. |
Impact | This has resulted in UCB supporting additional iCASE studentships in my group. A joint paper with UCB on a-synuclein has been published and 2 further collaborative papers with UCB are in the pipeline. |
Start Year | 2016 |
Description | "Cut & Paste" - genome editing (Royal Institution Family Fun day) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Other audiences |
Results and Impact | "Cut & Paste" - genome editing activities at the Royal Institution Family Fun day on 22nd February 2019. It comprised three activities explaining genome editing and its utilisation as a research tool |
Year(s) Of Engagement Activity | 2019 |
Description | "Understanding allergy - Itching, sneezing, wheezing" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Two 30 minute talks to 9/10 year students explaining the immune system and allergy. The talks were part of Wadham College Aspiration day 4th March 2019 - Academic taster session. |
Year(s) Of Engagement Activity | 2019 |
Description | All Party Parliamentary Group for Longevity - strategic advisory board member, also science, genomcis and technology board member |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | I have served on the APPG for Longevity strategic advisory board since its inception (I also pitched core ideas to the Department of Health concerning the science of ageing in advance of official launch of the APPG). As an SAB member, I have attended a number of meetings in parliament and in government departments, discussing how to achieves the government's stated aim of increasing legality lifespan by 5 years by 2035. We conducted a national consultation and the SAB were involved in analysing responses and coming up with an overall strategic approach to inform a National strategy on Ageing. As a member of the Science, genomics and technology board, I was asked to author a key paper for the National strategy report (see publications) |
Year(s) Of Engagement Activity | 2019,2020 |
URL | https://appg-longevity.org/advisory-board |
Description | Establishment of Oxford-wide ageing hub |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | The workshop brought together researchers from across the academic divisions of the university (medical sciences, maths, physical and life sciences, social sciences and humanities) to establish an Oxford ageing hub - this also included NHS representatives, public attendees and 3rd sector organisations with an interest in ageing and later life health. |
Year(s) Of Engagement Activity | 2019 |
Description | FUTURE OF PHARMA - ageing |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited participant in pharma workshop with major international players including politicians to discuss new ways of developing drugs to treat age-related diseases |
Year(s) Of Engagement Activity | 2020 |
Description | Founders Forum panellist |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Presented latest updates on ageing research to audience of company founders, and answered audience QS |
Year(s) Of Engagement Activity | 2019 |
Description | Geroscience masterclass |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | I organised, ran and presented a number of lectures at a 4 day gerosceince masterclass workshop to a group of net high worth individuals, philanthropists, business individuals and medical practitioners. |
Year(s) Of Engagement Activity | 2019 |
Description | How to academy talk on ageing therapies |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | I gave a public lecture on how to age well - new therapeutics for the How To Academy event on Longevity as part of UK's Longevity week (Nov 14th 2019) |
Year(s) Of Engagement Activity | 2019 |
Description | Interview with Longevity.technology |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Interview by Longevity.technology describing upcoming trends in ageing research, aimed mainly at investors and business. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.longevity.technology/this-isnt-all-snake-oil-interview-with-dr-lynne-cox/ |
Description | Invited keynote at Biopharma meeting, UCL 23rd Feb 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Undergraduate students |
Results and Impact | I gave a 1 hour invited presentation on prospects for developing new medicines for age-related diseases through understanding cellular senescence, and then sat on a discussion panel (with 2 other scientists) to take audience questions on the entire workshop. |
Year(s) Of Engagement Activity | 2019 |
Description | Launch of The Health of the Nation - a Strategy for Healthier Longer Lives (report of the All Party Parliamentary Group for Longevity) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | We launched the report of the APPG describing a roadmap to achieve the government's aim of 5 additional healthy years of life by 2035 (HLE+5) at a major event headlined by the Secretary of State for Health and Social Care, the Right Honourable Matt Hancock, the shadow secretary of State Jon ash worth and various other MPs from the House of Commons and House of Lords, as well as APPG advisory group members. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.youtube.com/watch?time_continue=3&v=tl7lJ1bj2lw&feature=emb_logo |
Description | Longevity Forum |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | I was a panellist at a longevity forum event at the Royal Institution in November 2019, presenting the latest in ageing research and taking Qs from the audience. |
Year(s) Of Engagement Activity | 2019 |
Description | Longevity Leaders 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | I gave a 1 hour presentation with Q+A at this major global event. |
Year(s) Of Engagement Activity | 2019 |
Description | Longevity forum: science of ageing workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Supporters |
Results and Impact | I co-oragnised and ran a one day workshop in Oxford as part of Longevity forum's longevity week (12th Nov 2019). |
Year(s) Of Engagement Activity | 2019 |
URL | https://thelongevityforum.com/the-longevity-week/ |
Description | Molecular Haematology Unit seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | A talk regarding the work on single-cell systems biology carried out by the company to date. This sparked a good debate between the presenter and the audience. |
Year(s) Of Engagement Activity | 2016,2017,2018,2019 |
Description | OxAgeN - establishment of the Oxford Aging Network (L. Cox) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Established a network of scientists and clinicians with an interest in ageing (research and clinical practice) to foster closer collaboration and accelerate discoveries from bench to clinic. Representatives from commercial organisations and third sector (U3A, Age UK) are also members. Impact: decision to hold scientific conference on ageing in Oxford. |
Year(s) Of Engagement Activity | 2015 |
URL | http://www.imm.ox.ac.uk/ageing |
Description | Oxford Science Festival |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Oxford Science Festival |
Year(s) Of Engagement Activity | 2016 |
Description | Podcast on progress in ageing therapeutics |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Podcast on ageing therapies as part of longevity week in London (14th Nov 2019) |
Year(s) Of Engagement Activity | 2019 |
URL | https://thelongevityforum.com/2020/01/16/podcast-with-lynne-cox-the-longevity-forum-2019/ |
Description | Public Engagement (Pint of Science) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Pint of Science talks aim to deliver the most recent/exciting scientific advances to the general public in a relaxed and informal setting. It is a platform for the general public to ask questions about scientific research, to the researchers carrying out the experiments! The aim is to broaden public interest in- and access to- scientific discoveries and data. Date of event: May 17th 2017. |
Year(s) Of Engagement Activity | 2017 |
URL | https://pintofscience.co.uk/events/oxford |
Description | Science Career Seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | A career talk to students and post-docs involving working in the USA |
Year(s) Of Engagement Activity | 2016 |
Description | Science club at Freeland Primary School |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Visit to Freeland Primary School on 14th January 2020 to carry out a 1h session comprising three activities with primary school students to explain DNA and genome editing. |
Year(s) Of Engagement Activity | 2020 |
Description | T cell differentation |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Schools |
Results and Impact | 1h session during Biology Summer School which took place at Wadham College on 21st August 2019. The activity looked at how naïve T cells differentiate into T cell subsets in vitro. |
Year(s) Of Engagement Activity | 2019 |
Description | Talk, OxAgeN meeting July 2015 (L. Cox) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Scientific presentation at Oxford Ageing Network meeting; outcome = agreed several collaborations and in discussion with possible industrial funders |
Year(s) Of Engagement Activity | 2015 |
Description | The Immune Cell Highway |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | The Immune Cell Highway was a session organised for Superdads Playgroup at Northway Church, Oxford on 8th February 2020. The activities were aimed at explaining how immune cells move around the body via two pathways - the blood & the lymphatics - and how this travelling is essential for clearing infections in the skin. |
Year(s) Of Engagement Activity | 2020 |
Description | The Immune Cell Highway (Swindon Science Festival) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | The Immune Cell Highway activity links the work being done in the Dong, Ogg and Jackson labs in the WIMM. They have created a stand explaining how immune cells move around the body via two pathways: the blood & the lymphatics. This activity was part of Swindon Science Festival on 21st and 22nd February 2020. |
Year(s) Of Engagement Activity | 2020 |
Description | Understanding allergy - Itching, sneezing, wheezing |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Two 30 minute sessions doing an "allergy testing" experiment with 9/10 year students. These sessions were part of Wadham College Aspiration Day - Academic taster session on 10th May 2019. |
Year(s) Of Engagement Activity | 2019 |